← All trials
NCT05900466
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Jun 12, 2023
- Last posted
- Oct 10, 2023
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UtahLead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- University of UtahOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.